Skip to main content
    N

    Novavax Inc (NVAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.06
    -0.46 (-5.45%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novavax Inc (NVAX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Novavax reported revenue of $1.12B for the fiscal year ended Dec 31, 2025, up 64.7% from the year before. That year, net income was $440.30M with a net margin of 39.2%, operating cash flow was -$244.63M and free cash flow was -$251.02M. The quarter ended Sep 30, 2026 had revenue of $68.30M and net income of -$31.38M.

    Revenue and Margins

    The operating margin was 40.3% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $15.35M, a compound annual rate of 61.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.12B+64.7%93.5%40.3%39.2%
    Dec 2024$682.16M-30.7%70.3%-36.5%-27.5%
    Dec 2023$983.71M-50.4%65.1%-57.6%-55.4%
    Dec 2022$1.98B+72.9%54.5%-32.5%-33.2%
    Dec 2021$1.15B+141.0%100.0%-147.1%-152.1%
    Dec 2020$475.60M+2448.5%100.0%-87.6%-87.9%
    Dec 2019$18.66MN/A100.0%-646.1%-711.0%
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$31.18M+103.1%100.0%-550.8%-589.5%
    Dec 2016$15.35MN/A100.0%-1752.8%-1823.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.12B$682.16M$983.71M$1.98B$1.15B$475.60M$18.66M$0$31.18M$15.35M
    Cost of revenue$73.04M$202.74M$343.77M$902.64M$0$0$0$0$0$0
    Gross profit$1.05B$479.42M$639.94M$1.08B$1.15B$475.60M$18.66M$0$31.18M$15.35M
    Research and development$342.32M$391.17M$737.50M$1.24B$2.53B$747.03M$113.84M$173.80M$168.44M$237.94M
    Operating income$452.80M-$248.93M-$566.51M-$644.74M-$1.69B-$416.72M-$120.58M-$173.92M-$171.71M-$269.11M
    Net income$440.30M-$187.50M-$545.06M-$657.94M-$1.74B-$418.26M-$132.69M-$184.75M-$183.77M-$279.97M
    EBITDA$521.04M-$108.04M-$487.39M-$604.71M-$1.68B-$398.23M-$114.92M-$164.23M-$160.40M-$259.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$68.30M$56.70M$139.51M$147.14M$70.44M$239.24M$666.65M$88.31M$84.51M$415.48M$93.86M$291.34M
    Gross profit$44.81M$42.45M$108.82M$125.03M$48.95M$223.91M$652.54M$51.64M$23.89M$369.24M$34.65M$136.37M
    Operating income-$31.28M-$54.91M-$15.43M$14.23M-$178.02M$101.07M$515.51M-$131.08M-$134.02M$161.00M-$144.83M-$183.57M
    Net income-$31.38M-$53.39M-$9.49M$17.53M-$202.38M$106.51M$518.65M-$81.03M-$121.30M$162.38M-$147.55M-$178.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $246.72M exceeded cash and equivalents by $6.09M. Shareholder equity was negative, at -$127.75M, as total liabilities of $1.30B exceeded total assets of $1.18B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.18B$1.56B$1.80B$2.26B$2.58B$1.58B$172.96M$207.98M$302.49M$394.30M
    Current assets$978.28M$1.13B$1.14B$1.70B$2.16B$1.25B$97.25M$119.28M$203.31M$287.83M
    Cash and equivalents$240.63M$530.23M$568.50M$1.34B$1.52B$553.40M$78.82M$70.15M$106.31M$144.35M
    Total liabilities$1.30B$2.18B$2.51B$2.89B$2.93B$955.27M$358.97M$375.91M$404.23M$399.85M
    Short-term debt$2.51M$7.01M$5.14M$324.88M$0$322.04M$1.26M$24.63M$34.69M$29.59M
    Long-term debt$244.21M$169.68M$168.02M$166.47M$323.46M$322.04M$320.61M$319.19M$317.76M$316.34M
    Shareholder equity-$127.75M-$623.84M-$716.93M-$634.08M-$351.67M$627.21M-$186.02M-$167.94M-$101.73M-$5.55M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$888.00M$955.58M$1.04B$1.18B$1.18B$1.34B$1.29B$1.56B$1.71B$1.82B$1.35B$1.80B
    Total liabilities$1.10B$1.15B$1.19B$1.30B$1.34B$1.30B$1.37B$2.18B$2.24B$2.25B$2.22B$2.51B
    Cash and equivalents$222.46M$191.46M$228.36M$240.63M$268.02M$253.74M$263.34M$530.23M$573.63M$680.16M$480.59M$568.50M
    Shareholder equity-$216.85M-$190.71M-$144.76M-$127.75M-$156.67M$37.63M-$75.64M-$623.84M-$526.44M-$431.71M-$867.08M-$716.93M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$244.63M-$87.26M-$713.97M-$415.94M$322.95M-$42.54M-$136.62M-$184.82M-$144.48M-$258.77M
    Capital expenditures$6.39M$14.64M$58.81M$92.98M$57.49M$54.62M$1.86M$1.37M$4.19M$18.20M
    Free cash flow-$251.02M-$101.90M-$772.77M-$508.92M$265.46M-$97.16M-$138.48M-$186.20M-$148.66M-$276.97M
    Dividends paidN/AN/AN/AN/AN/A$39.09MN/AN/A$0$0
    Share repurchases$0$0$3.59M$5.26M$0N/AN/AN/AN/AN/A
    Investing cash flow-$78.27M-$204.04M-$58.81M-$92.98M$100.15M-$377.78M$38.49M$28.60M$35.97M$28.02M
    Financing cash flow$27.74M$260.58M$4.47M$324.99M$461.71M$984.76M$98.38M$102.81M$64.54M$279.85M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$94.24M-$72.81M-$32.42M-$39.48M$107.80M-$127.46M-$185.50M-$173.16M-$144.81M$314.27M-$83.56M-$176.78M
    Capital expenditures$1.02M$588.00K$1.27M$2.25M$2.02M$527.00K$1.59M$2.25M$2.01M$3.13M$7.25M$9.08M
    Free cash flow-$95.26M-$73.39M-$33.69M-$41.72M$105.79M-$127.99M-$187.10M-$175.41M-$146.83M$311.14M-$90.81M-$185.86M
    Last 12 quarters

    Frequently Asked Questions About NVAX

    What is Novavax's annual revenue?

    Novavax reported revenue of $1.12B for the fiscal year ended Dec 31, 2025.

    How fast is Novavax's revenue growing?

    Revenue was up 64.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -17.2%.

    Is Novavax profitable?

    Yes. Novavax reported net income of $440.30M for the fiscal year ended Dec 31, 2025, with a net margin of 39.2%.

    How much free cash flow does NVAX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$244.63M minus capital expenditures of $6.39M produced free cash flow of -$251.02M.

    How much debt does Novavax have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $244.21M, short-term debt of $2.51M and cash and equivalents of $240.63M.